Context Therapeutics INC 10-Q quarterly reports

Context Therapeutics Inc. reported a net loss of $8.7 million for Q1 2026, with a significant increase in R&D expenses to advance its pipeline, while maintaining a cash runway projected into mid-2027.

Context Therapeutics reports reduced net losses and pipeline progress for its T cell engager bispecific antibodies, extending its cash runway into 2027.

Context Therapeutics reported a wider net loss in Q2 2025 due to increased research and development expenses as it advanced its bispecific antibody pipeline, including CTIM-76 and CT-95, into Phase 1 trials.

Context Therapeutics reports a net loss of $4.6 million for Q1 2025 and highlights progress in clinical trials for its bispecific antibody candidates.

Context Therapeutics reported its third quarter 2024 financial results, highlighting progress in its bispecific antibody programs and a significant increase in cash reserves following a private placement.

Context Therapeutics reported its second quarter 2024 financial results, highlighted by a significant increase in cash reserves following a private placement and advancements in its clinical programs.

Context Therapeutics reported a net loss of $3.7 million for the first quarter of 2024, while also securing a significant $100 million private placement to advance its clinical programs.